Proton-pump inhibitor use and hip fractures in men: a population-based case-control study

被引:43
作者
Adams, Annette L. [1 ]
Black, Mary Helen [1 ]
Zhang, Jian L. [1 ]
Shi, Jiaxiao M. [1 ]
Jacobsen, Steven J. [1 ]
机构
[1] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA
关键词
Epidemiology; Pharmacoepidemiology; Proton pump inhibitor; PPI; Hip fractures; BONE-MINERAL DENSITY; RISK; METAANALYSIS; THERAPY; MEDICATIONS; WOMEN;
D O I
10.1016/j.annepidem.2014.01.004
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose: To estimate the association between proton-pump inhibitor (PPI) use and hip fracture. Methods: We conducted a case-control study of 6774 pairs of men aged 45 years or older, matched on age, race, and medical center. Cases sustained incident hip fractures in 1997-2006. Fracture date was index date for each case-control pair. PPI exposure was identified from electronic pharmacy records, 1991-2006. PPI use was measured as (1) ever versus never; (2) adherence; (3) duration; and (4) recentness. Omeprazole and pantoprazole were analyzed separately using conditional logistic regression, adjusted for comorbidities. Nonusers were the referent group. Results: Eight hundred ninety-six (13.2%) cases and 713 (10.5%) controls used omeprazole before index date (matched odds ratio [OR], 1.13; 95% confidence interval [CI], 1.01-1.27). Greatest adherence (medication possession ratio > 80%) (OR, 1.33; 95% CI, 1.09-1.62), highest tertile of duration (OR, 1.23; 95% CI, 1.02-1.48), and recent use (OR, 1.22; 95% CI, 1.02-1.47) were associated with hip fracture. Six hundred ninety-four (10.2%) cases and 576 (8.5%) controls had used pantoprazole (OR, 1.10; 95% CI, 0.97-1.24). Longest duration (OR, 1.25; 95% CI, 1.02-1.53) and most recent use (OR, 1.38; 95% CI, 1.12-1.71) were associated with hip fracture. Our study suggests that PPI use and hip fractures are associated, with risk increasing with longer duration and more recent use. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:286 / 290
页数:5
相关论文
共 29 条
  • [1] Methods for evaluation of medication adherence and persistence using automated databases
    Andrade, Susan E.
    Kahler, Kristijan H.
    Frech, Feride
    Chan, K. Arnold
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 (08) : 565 - 574
  • [2] [Anonymous], 2004, Bone Health and Osteoporosis: A report of the Surgeon General
  • [3] [Anonymous], 2011, US MED US REV 2010
  • [4] Bergstralh EJ, 1996, EPIDEMIOLOGY, V7, P331
  • [5] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION
    CHARLSON, ME
    POMPEI, P
    ALES, KL
    MACKENZIE, CR
    [J]. JOURNAL OF CHRONIC DISEASES, 1987, 40 (05): : 373 - 383
  • [6] Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study
    Chiu, Hui-Fen
    Huang, Ya-Wen
    Chang, Chih-Ching
    Yang, Chun-Yuh
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 (11) : 1131 - 1136
  • [7] Proton Pump Inhibitors and Histamine-2 Receptor Antagonists Are Associated With Hip Fractures Among At-Risk Patients
    Corley, Douglas A.
    Kubo, Ai
    Zhao, Wei
    Quesenberry, Charles
    [J]. GASTROENTEROLOGY, 2010, 139 (01) : 93 - 101
  • [8] Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates
    de Vries, F.
    Cooper, A. L.
    Cockle, S. M.
    van Staa, T-P.
    Cooper, C.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2009, 20 (12) : 1989 - 1998
  • [9] ADAPTING A CLINICAL COMORBIDITY INDEX FOR USE WITH ICD-9-CM ADMINISTRATIVE DATABASES
    DEYO, RA
    CHERKIN, DC
    CIOL, MA
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1992, 45 (06) : 613 - 619
  • [10] Use of Acid-Suppressive Drugs and Risk of Fracture: A Meta-analysis of Observational Studies
    Eom, Chun-Sick
    Park, Sang Min
    Myung, Seung-Kwon
    Yun, Jae Moon
    Ahn, Jeong-Soo
    [J]. ANNALS OF FAMILY MEDICINE, 2011, 9 (03) : 257 - 267